* Biora Therapeutics Inc BIOR.OQ BIOR.O is expected
to report
results on May 8 (estimated).
*
* Refinitiv's mean analyst estimate for Biora Therapeutics
Inc is
for a loss of $1.75 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Biora
Therapeutics Inc is $65, above its last closing price
of $2.46.
This summary was machine generated May 5 at 14:37 GMT. All
figures in US dollars unless otherwise stated